ERBB2 and breast carcinoma: Zhang et al. used T7 peptide modified liposomes as a carrier for transporting HER2 inhibitors, which can actively target breast cancer tumors and reduce the toxicity to normal tissues.227 Gao et al. also confirmed that T7 peptide-modified polymers exhibited higher cell uptake efficiency and rapid endosomal/lysosome escape ability in breast cancer MCF-7.